Evidence map›Paper›PMID 37274321›Full record

ArticleFrontiers in endocrinology2023

Canagliflozin on top of dual renin-angiotensin system blockade in a woman with partial acquired lipodystrophy, type 2 diabetes and severely proteinuric chronic kidney disease: a case report.

Edoardo Biancalana, Giovanni Ceccarini, Silvia Magno, Valerio Ortenzi, Domenico Giannese, Ferruccio Santini, Anna Solini

Open access · goldFull text readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Edoardo BiancalanaDepartment of Clinical and Experimental Medicine University of Pisa, Pisa, Italy.
Giovanni CeccariniObesity and Lipodistrophy Center, University Hospital of Pisa, Pisa, Italy.
Silvia MagnoObesity and Lipodistrophy Center, University Hospital of Pisa, Pisa, Italy.
Valerio OrtenziSection of Pathology, University Hospital of Pisa, Pisa, Italy.
Domenico GianneseNephrology Unit, University Hospital of Pisa, Pisa, Italy.
Ferruccio SantiniObesity and Lipodistrophy Center, University Hospital of Pisa, Pisa, Italy.
Anna SoliniDepartment of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy.
Azienda Ospedaliera Universitaria Pisana · ITUniversity of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sodium glucose cotransporter 2 inhibitors have proven strong efficacy in reducing end-stage renal disease in patients with type 2 diabetes. We are presenting here the case of a 40-year-old woman with acquired partial lipodystrophy, type 2 diabetes and essential hypertension complicated by chronic kidney disease and proteinuria in the nephrotic range. She first came to our attention in 2012; estimated glomerular filtration rate (eGFR) was 41.5 ml/min/1.73 m

Indexed as

Diabetes Mellitus, Type 2LipodystrophyRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsAdultCanagliflozinFemaleHumansProteinuriaRenin-Angiotensin SystemCanagliflozinSodium-Glucose Transporter 2 Inhibitorscanagliflozincase reportdual renin-angiotensin system blockadelipodystrophymetreleptinproteinuria

Identifiers

PMID37274321
PMCPMC10237351
OpenAlexW4377139113

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.